de la Guerra, Sheila Public Comment

D-1

From: Sent:

Justin Shores <j_shores@hotmail.com> Monday, September 20, 2021 4:48 PM

To: Subject:

sbcob lvermectin Late. Dist.

Caution: This email originated from a source outside of the County of Santa Barbara. Do not click links or open attachments unless you verify the sender and know the content is safe.

Good Evening,

Last week Supervisor Hartmann stated that ivermectin is only for horses. This statement was either ignorant or malicious. Doctor De Reynoso has also ignored this treatment in favor of the more profitable and problematic vaccine. Why?

Justin Shores


https://pubmed.ncbi.nlm.nih.gov/34145166

Therapeutic advances: Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian-Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff-Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%-91%). Secondary outcomes provided less certain evidence. Low-certainty evidence suggested that there may be no benefit with ivermectin for "need for mechanical ventilation," whereas effect estimates for "improvement" and "deterioration" clearly favored ivermectin use. Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty.

https://ivmmeta.com/

- •Meta analysis using the most serious outcome reported shows 68% [52-78%] and 86% [75-92%] improvement for <u>early treatment and prophylaxis</u>, with similar results after <u>exclusion based sensitivity analysis</u> and restriction to <u>peer-reviewed studies</u> or <u>Randomized Controlled Trials</u>.
- •Statistically significant improvements are seen for<u>mortality</u>, <u>ventilation</u>, <u>hospitalization</u>, <u>recovery</u>, <u>cases</u>, and <u>viral clearance</u>. 29 studies show statistically significant improvements in isolation.

Evolutionary pressure on viruses to spe mutations?




Normalized to fully injected

There are ~1500
Immunological AEs occurring per million fully-injected people – that is a lot of CV
AEs...

4 3/21

1/660 individuals report an immunological AE in context of COVID-19 products




rata cource, with \$50 Amargons. Dr. sessious 8000

*As of August 27th, 2021

Total VAERS counts and death counts

Total VAERS reports per year



Atypical (Update as of September 3rd, 2021)

9/15/21

Data source: VATRS Dements data Analysis Or cass